AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
evogliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| dipeptidyl aminopeptidase-IV inhibitors | 5239 | 1222102-29-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Evogliptin is an orally bioavailable, selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 5 | mg | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MET,NTRK2,PDK1,PDK2,PDK4,PRKDC,TGFBR1 | 16 | |||
| kinase-selectivity-class | AXL,BRAF,GRK2 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 2, 2015 | Korean Food and Drug Administration (KFDA) | Dong-A ST |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BD22 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
| ATC | A10BH07 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Dipeptidyl peptidase 4 (DPP-4) inhibitors |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Related Drugs by ATC class:
A10BD Combinations of oral blood glucose lowering drugs 19 drugs
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.97 | acidic |
| pKa2 | 8.14 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Dipeptidyl peptidase 4 | Enzyme | INHIBITOR | IC50 | 9.05 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 09118300L7 | UNII |
| C4279601 | UMLSCUI |
| CHEBI:750182 | CHEBI |
| CHEMBL1779710 | ChEMBL_ID |
| 25022354 | PUBCHEM_CID |
| DB12625 | DRUGBANK_ID |
| D11023 | KEGG_DRUG |
| 9654 | INN_ID |
| C557982 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8VU | PDB_CHEM_ID |
Pharmaceutical products:
None